News | January 28, 2026
Parse Biosciences unveils integrated immune profiling in Trailmaker Platform
The new functionality complements Parse’s existing Evercode immune products
The new functionality complements Parse’s existing Evercode immune products
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Subscribe To Our Newsletter & Stay Updated
